GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?

Robert P Young1,2, Raewyn J Hopkins1, Bryan A Hay1, Gregory D Gamble11Schools of Biological Science and Health Sciences, University of Auckland, 2Department of Medicine, Auckland City Hospital, Auckland, New ZealandBackground: Studies over the past two decades have reported associations between GSTM...

Full description

Bibliographic Details
Main Authors: Young RP, Hopkins RJ, Hay BA, Gamble GD
Format: Article
Language:English
Published: Dove Medical Press 2011-09-01
Series:The Application of Clinical Genetics
Online Access:http://www.dovepress.com/gstm1-null-genotype-in-copd-and-lung-cancer-evidence-of-a-modifier-or--a8275
id doaj-6ab110d096754497a2a1df034a8ad5f6
record_format Article
spelling doaj-6ab110d096754497a2a1df034a8ad5f62020-11-24T23:47:24ZengDove Medical PressThe Application of Clinical Genetics1178-704X2011-09-012011default137144GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?Young RPHopkins RJHay BAGamble GDRobert P Young1,2, Raewyn J Hopkins1, Bryan A Hay1, Gregory D Gamble11Schools of Biological Science and Health Sciences, University of Auckland, 2Department of Medicine, Auckland City Hospital, Auckland, New ZealandBackground: Studies over the past two decades have reported associations between GSTM1 (glutathione S-transferase mu 1) null genotype and chronic obstructive pulmonary disease (COPD) or lung cancer. However, a modifier or confounding effect from COPD mediating the GSTM1 association with lung cancer has not been previously explored.Aim and methods: This variant was examined in a case-control study of current or former smokers with COPD (n = 669), lung cancer (n = 454), or normal lung function (n = 488). Sex, age, and smoking history were comparable between groups.Results: The GSTM1 null genotype was found to be more frequent in smokers with COPD alone (odds ratio [OR] 1.30, 95% confidence interval [CI] 1.02–1.66, P = 0.031) and lung cancer (OR 1.26, 95% CI 0.96–1.65, P = 0.083) than in matched smokers with normal lung function (62%, 61%, and 56%, respectively). However, when smokers with lung cancer were subgrouped according to the presence of COPD, then the association with all COPD subjects (OR 1.34, 95% CI 1.07–1.70, P = 0.010) and with COPD and lung cancer (OR 1.50, 95% CI 1.06–2.12, P = 0.018) continued to be significant while that with lung cancer only was reduced (OR 1.11, 95% CI 0.78–1.56, P = 0.55). These associations were independent of age, sex, height, lung function, and smoking history.Conclusion: Findings suggest that COPD is an important subphenotype of lung cancer and may underlie previously reported associations with the GSTM1 null genotype.Keywords: lung cancer, chronic obstructive pulmonary disease, GSTM1, association study, polymorphism, copy number varianthttp://www.dovepress.com/gstm1-null-genotype-in-copd-and-lung-cancer-evidence-of-a-modifier-or--a8275
collection DOAJ
language English
format Article
sources DOAJ
author Young RP
Hopkins RJ
Hay BA
Gamble GD
spellingShingle Young RP
Hopkins RJ
Hay BA
Gamble GD
GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?
The Application of Clinical Genetics
author_facet Young RP
Hopkins RJ
Hay BA
Gamble GD
author_sort Young RP
title GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?
title_short GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?
title_full GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?
title_fullStr GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?
title_full_unstemmed GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?
title_sort gstm1 null genotype in copd and lung cancer: evidence of a modifier or confounding effect?
publisher Dove Medical Press
series The Application of Clinical Genetics
issn 1178-704X
publishDate 2011-09-01
description Robert P Young1,2, Raewyn J Hopkins1, Bryan A Hay1, Gregory D Gamble11Schools of Biological Science and Health Sciences, University of Auckland, 2Department of Medicine, Auckland City Hospital, Auckland, New ZealandBackground: Studies over the past two decades have reported associations between GSTM1 (glutathione S-transferase mu 1) null genotype and chronic obstructive pulmonary disease (COPD) or lung cancer. However, a modifier or confounding effect from COPD mediating the GSTM1 association with lung cancer has not been previously explored.Aim and methods: This variant was examined in a case-control study of current or former smokers with COPD (n = 669), lung cancer (n = 454), or normal lung function (n = 488). Sex, age, and smoking history were comparable between groups.Results: The GSTM1 null genotype was found to be more frequent in smokers with COPD alone (odds ratio [OR] 1.30, 95% confidence interval [CI] 1.02–1.66, P = 0.031) and lung cancer (OR 1.26, 95% CI 0.96–1.65, P = 0.083) than in matched smokers with normal lung function (62%, 61%, and 56%, respectively). However, when smokers with lung cancer were subgrouped according to the presence of COPD, then the association with all COPD subjects (OR 1.34, 95% CI 1.07–1.70, P = 0.010) and with COPD and lung cancer (OR 1.50, 95% CI 1.06–2.12, P = 0.018) continued to be significant while that with lung cancer only was reduced (OR 1.11, 95% CI 0.78–1.56, P = 0.55). These associations were independent of age, sex, height, lung function, and smoking history.Conclusion: Findings suggest that COPD is an important subphenotype of lung cancer and may underlie previously reported associations with the GSTM1 null genotype.Keywords: lung cancer, chronic obstructive pulmonary disease, GSTM1, association study, polymorphism, copy number variant
url http://www.dovepress.com/gstm1-null-genotype-in-copd-and-lung-cancer-evidence-of-a-modifier-or--a8275
work_keys_str_mv AT youngrp gstm1nullgenotypeincopdandlungcancerevidenceofamodifierorconfoundingeffect
AT hopkinsrj gstm1nullgenotypeincopdandlungcancerevidenceofamodifierorconfoundingeffect
AT hayba gstm1nullgenotypeincopdandlungcancerevidenceofamodifierorconfoundingeffect
AT gamblegd gstm1nullgenotypeincopdandlungcancerevidenceofamodifierorconfoundingeffect
_version_ 1725489889764442112